304 related articles for article (PubMed ID: 21751810)
1. Catechol polymers for pH-responsive, targeted drug delivery to cancer cells.
Su J; Chen F; Cryns VL; Messersmith PB
J Am Chem Soc; 2011 Aug; 133(31):11850-3. PubMed ID: 21751810
[TBL] [Abstract][Full Text] [Related]
2. Tumor extracellular acidity activated "off-on" release of bortezomib from a biocompatible dendrimer.
Wang M; Wang Y; Hu K; Shao N; Cheng Y
Biomater Sci; 2015 Mar; 3(3):480-9. PubMed ID: 26222291
[TBL] [Abstract][Full Text] [Related]
3. Boronate-crosslinked polysaccharide conjugates for pH-responsive and targeted drug delivery.
Zhang YH; Zhang YM; Yu J; Wang J; Liu Y
Chem Commun (Camb); 2019 Jan; 55(8):1164-1167. PubMed ID: 30632564
[TBL] [Abstract][Full Text] [Related]
4. Dual pH-Responsive Shell-Cleavable Polycarbonate Micellar Nanoparticles for in Vivo Anticancer Drug Delivery.
Liu S; Ono RJ; Yang C; Gao S; Ming Tan JY; Hedrick JL; Yang YY
ACS Appl Mater Interfaces; 2018 Jun; 10(23):19355-19364. PubMed ID: 29757607
[TBL] [Abstract][Full Text] [Related]
5. Use of pH-Active Catechol-Bearing Polymeric Nanogels with Glutathione-Responsive Dissociation to Codeliver Bortezomib and Doxorubicin for the Synergistic Therapy of Cancer.
Qiu Y; Bai J; Feng Y; Shi X; Zhao X
ACS Appl Mater Interfaces; 2021 Aug; 13(31):36926-36937. PubMed ID: 34319074
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib-catechol conjugated prodrug micelles: combining bone targeting and aryl boronate-based pH-responsive drug release for cancer bone-metastasis therapy.
Zhu J; Huo Q; Xu M; Yang F; Li Y; Shi H; Niu Y; Liu Y
Nanoscale; 2018 Oct; 10(38):18387-18397. PubMed ID: 30256367
[TBL] [Abstract][Full Text] [Related]
7. Dietary Flavonoids with Catechol Moiety Inhibit Anticancer Action of Bortezomib: What about the other Boronic Acid-based Drugs?
Sak K
Curr Cancer Drug Targets; 2022; 22(9):741-748. PubMed ID: 35578889
[TBL] [Abstract][Full Text] [Related]
8. Drug release and kinetic models of anticancer drug (BTZ) from a pH-responsive alginate polydopamine hydrogel: Towards cancer chemotherapy.
Rezk AI; Obiweluozor FO; Choukrani G; Park CH; Kim CS
Int J Biol Macromol; 2019 Dec; 141():388-400. PubMed ID: 31493453
[TBL] [Abstract][Full Text] [Related]
9. pH/sugar dual responsive core-cross-linked PIC micelles for enhanced intracellular protein delivery.
Ren J; Zhang Y; Zhang J; Gao H; Liu G; Ma R; An Y; Kong D; Shi L
Biomacromolecules; 2013 Oct; 14(10):3434-43. PubMed ID: 24063314
[TBL] [Abstract][Full Text] [Related]
10. Dual-acidity-labile polysaccharide-di-drugs conjugate for targeted cancer chemotherapy.
Li D; Su T; Ma L; Yin F; Xu W; Ding J; Li Z
Eur J Med Chem; 2020 Aug; 199():112367. PubMed ID: 32474350
[TBL] [Abstract][Full Text] [Related]
11. Noncompetitive modulation of the proteasome by imidazoline scaffolds overcomes bortezomib resistance and delays MM tumor growth in vivo.
Lansdell TA; Hurchla MA; Xiang J; Hovde S; Weilbaecher KN; Henry RW; Tepe JJ
ACS Chem Biol; 2013 Mar; 8(3):578-87. PubMed ID: 23198928
[TBL] [Abstract][Full Text] [Related]
12. Biotinylated HPMA centered polymeric nanoparticles for Bortezomib delivery.
Rani S; Sahoo RK; Nakhate KT; Ajazuddin ; Gupta U
Int J Pharm; 2020 Apr; 579():119173. PubMed ID: 32097684
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells.
Kazi A; Lawrence H; Guida WC; McLaughlin ML; Springett GM; Berndt N; Yip RM; Sebti SM
Cell Cycle; 2009 Jun; 8(12):1940-51. PubMed ID: 19471122
[TBL] [Abstract][Full Text] [Related]
14. Development of P22 viral capsid nanocomposites as anti-cancer drug, bortezomib (BTZ), delivery nanoplatforms.
Min J; Moon H; Yang HJ; Shin HH; Hong SY; Kang S
Macromol Biosci; 2014 Apr; 14(4):557-64. PubMed ID: 24847525
[TBL] [Abstract][Full Text] [Related]
15. An implantable smart magnetic nanofiber device for endoscopic hyperthermia treatment and tumor-triggered controlled drug release.
Sasikala ARK; Unnithan AR; Yun YH; Park CH; Kim CS
Acta Biomater; 2016 Feb; 31():122-133. PubMed ID: 26687978
[TBL] [Abstract][Full Text] [Related]
16. Enzymatic multifunctional biodegradable polymers for pH- and ROS-responsive anticancer drug delivery.
Su M; Xiao S; Shu M; Lu Y; Zeng Q; Xie J; Jiang Z; Liu J
Colloids Surf B Biointerfaces; 2020 Sep; 193():111067. PubMed ID: 32388121
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and in vitro evaluation of a pH-sensitive PLA-PEG-folate based polymeric micelle for controlled delivery of docetaxel.
Hami Z; Amini M; Ghazi-Khansari M; Rezayat SM; Gilani K
Colloids Surf B Biointerfaces; 2014 Apr; 116():309-17. PubMed ID: 24503352
[TBL] [Abstract][Full Text] [Related]
18. Tumor-targeting, pH-responsive, and stable unimolecular micelles as drug nanocarriers for targeted cancer therapy.
Yang X; Grailer JJ; Pilla S; Steeber DA; Gong S
Bioconjug Chem; 2010 Mar; 21(3):496-504. PubMed ID: 20163170
[TBL] [Abstract][Full Text] [Related]
19. pH-responsive robust polymer micelles with metal-ligand coordinated core cross-links.
Hwang GH; Min KH; Lee HJ; Nam HY; Choi GH; Kim BJ; Jeong SY; Lee SC
Chem Commun (Camb); 2014 Apr; 50(33):4351-3. PubMed ID: 24643304
[TBL] [Abstract][Full Text] [Related]
20. Characterization of bortezomib-adapted I-45 mesothelioma cells.
Zhang L; Littlejohn JE; Cui Y; Cao X; Peddaboina C; Smythe WR
Mol Cancer; 2010 May; 9():110. PubMed ID: 20482802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
